Taiwan Country Commercial Guide
Learn about the market conditions, opportunities, regulations, and business conditions in taiwan, prepared by at U.S. Embassies worldwide by Commerce Department, State Department and other U.S. agencies’ professionals
Select Country Guide
Biotechnologies
Last published date:

Market Overview

Taiwan’s biotechnology policy is closely aligned with global trends and offers strong opportunities for U.S. exporters of innovative medical technologies and services and for U.S. localities seeking high-tech foreign direct investment. The government is actively promoting sectors such as regenerative medicine, precision medicine, and digital health to support the island’s aging population and meet rising healthcare demands. Initiatives like the Age-Tech Industry Action Plan, combined with cross-ministerial collaboration and investment incentives, create a welcoming environment for innovative technologies, research partnerships, and startup formation.

Taiwan has developed a robust biotech ecosystem with strong R&D capacity, skilled talent, and access to both public and private funding. The industry is adept at commercializing research, transferring technologies from academia, and introducing advanced foreign technologies. Taiwan’s regulatory environment is increasingly harmonized with international standards, making it easier for U.S. companies to navigate the market and pursue licensing, joint ventures, or contract manufacturing.

Key legislation—including the Act for the Development of Biotech and Pharmaceutical Industry, the Regenerative Medicine Act, and revised telemedicine regulations—supports product development and market entry. As of July 2024, 211 companies and 533 products have qualified under the Biotech Development Act, with 84 products launched domestically and internationally. These legal frameworks offer tax incentives and encourage investment in high-risk medical devices, biologics, CDMO services, and advanced digital health platforms.

In 2023, Taiwan’s biotech and pharmaceutical industry generated NT$ 757.8 billion (approx. $ 24.5 billion) in revenue, an 8.12% increase over the previous year. Private sector investment reached over NT$ 55 billion (approx. $ 1.8 billion), and 134 biotech companies are now publicly listed with a combined market capitalization exceeding NT$ 1.3 trillion (approx. $ 42.4 billion).

Taiwan also offers unique advantages as a regional partner: a high-quality universal healthcare system, a comprehensive national health insurance database, and global leadership in ICT and semiconductor manufacturing. The government is actively supporting the development of biomedical big data applications, AI-driven health solutions, and smart manufacturing—areas where U.S. companies can contribute expertise, technologies, or services. As Taiwan advances its “2030 All-Age Precision Health Vision,” the government is focused on international cooperation, public-private partnerships, and fostering a human-centered, innovation-driven health system. U.S. exporters of medical devices, biologics, health IT, AI health solutions, and manufacturing services are well positioned to benefit from this growing and globally connected market.

Table: Taiwan Biotechnology Market Size, Units: US$ millions 

 

2022

2023

2024 (estimated)

2025 (estimated)

Total Exports 

5,873

6,327

6,726

4,068

Total Imports 

12,491

10,892

11,622

7,003

Imports from the US 

2,490

2,176

2,323

1,399

Exchange Rates 

29.78 

31.15 

32.11 

29.30 (as of July 15, 2025)

Source: 1) 2024 Biotechnology Industry of Taiwan, Industry Development Administration, MOEA
              2) Taiwan Customs and Ministry of Finance: service.mof.gov.tw

Leading Sub-sectors

  • Pharmaceuticals & Biologics

  • Medical Devices & Diagnostics

  • Digital Health & Precision Medicine

  • Advanced Therapies (ATMPs)

Opportunities

Pharmaceuticals & Biologics

  • Novel biologics (oncology, autoimmune, rare diseases)

  • Orphan drugs and gene/cell therapies

  • Biosimilars and specialty injectables

Opportunities:

  • Co-development partnerships with local biotech firms

  • Licensing agreements and regional commercialization

Medical Devices & Diagnostics

  • In vitro diagnostics (IVD) and companion diagnostics

  • AI-powered imaging, screening, and wearable devices

  • Smart surgical systems and minimally invasive equipment

Digital Health & Precision Medicine

  • Genomic analysis platforms

  • AI-enabled diagnostics and treatment decision software

  • Telemedicine and remote monitoring tools

Opportunities:

  • Taiwan’s centralized health records and 25+ years of population-level health data make it ideal for AI and real-world evidence pilots

Advanced Therapies (ATMPs)

  • Taiwan is investing in cell therapy GMP centers and hospital-based regenerative medicine platforms

  • Demand for CAR-T manufacturing tools, viral vectors, and GMP facility equipment

  • Potential for U.S.-Taiwan joint development projects in cancer, neurodegenerative, and rare disease applications

Resources

  • BIO Asia–Taiwan 2026 – International Conference & Exhibition
    Dates: July 16–19, 2026
    Venue: Taipei Nangang Exhibition Center, Hall 1, 4F (TaiNEX 1)

  • MEDICAL TAIWAN
    Dates (2026): / June 25–27, 2026
    Venue: Taipei Nangang Exhibition Center

  • Healthcare+ Expo Taiwan (also known as Taiwan Healthcare+ Expo)
    Dates (2026 expected): December 2026 (dates typically early December)
    Venue: Taipei Nangang Exhibition Center

Relevant Authorities and Associations

  • Taiwan Food and Drug Administration (TFDA)

  • Ministry of Health and Welfare (MOHW)

  • National Health Insurance Administration (NHIA)

  • Ministry of Health and Welfare

  • Ministry of Economic Affairs (MOEA)

  • Industrial Development Administration (IDA) / Biotech and Pharmaceutical Industries Promotion Office (BPIPO)

  • National Biotechnology Research Park (NBRP)

  • Taiwan Bio Industry Organization

×

Global Business Navigator Chatbot Beta

Welcome to the Global Business Navigator, an artificial intelligence (AI) Chatbot from the International Trade Administration (ITA). This tool, currently in beta version testing, is designed to provide general information on the exporting process and the resources available to assist new and experienced U.S. exporters. The Chatbot, developed using Microsoft’s Azure AI services, is trained on ITA’s export-related content and aims to quickly get users the information they need. The Chatbot is intended to make the benefits of exporting more accessible by understanding non-expert language, idiomatic expressions, and foreign languages.

Limitations

As a beta product, the Chatbot is currently being tested and its responses may occasionally produce inaccurate or incomplete information. The Chatbot is trained to decline out of scope or inappropriate requests. The Chatbot’s knowledge is limited to the public information on the Export Solutions web pages of Trade.gov, which covers a wide range of topics on exporting. While it cannot provide responses specific to a company’s product or a specific foreign market, its reference pages will guide you to other relevant government resources and market research. Always double-check the Chatbot’s responses using the provided references or by visiting the Export Solutions web pages on Trade.gov. Do not use its responses as legal or professional advice. Inaccurate advice from the Chatbot would not be a defense to violating any export rules or regulations.

Privacy

The Chatbot does not collect information about users and does not use the contents of users’ chat history to learn new information. All feedback is anonymous. Please do not enter personally identifiable information (PII), sensitive, or proprietary information into the Chatbot. Your conversations will not be connected to other interactions or accounts with ITA. Conversations with the Chatbot may be reviewed to help ITA improve the tool and address harmful, illegal, or otherwise inappropriate questions.

Translation

The Chatbot supports a wide range of languages. Because the Chatbot is trained in English and responses are translated, you should verify the translation. For example, the Chatbot may have difficulty with acronyms, abbreviations, and nuances in a language other than English.

Privacy Program | Information Quality Guidelines | Accessibility